Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective

Aim: Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS), particularly when resistant to standard treatments. Acthar R Gel, a Food and Drug Administration (FDA)-approved treatment, may be a potential option for proteinuria in nephrotic syndrome (NS) due to FSGS,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jas Bindra, Ishveen Chopra, Kyle Hayes, John Niewoehner, Mary Panaccio, George J Wan
Format:	Artigo
Idioma:	Inglês
Publicat:	Becaris Publishing Limited 2026-01-01
Col·lecció:	Journal of Comparative Effectiveness Research
Matèries:	acthar gel cost-per-response focal segmental glomerulosclerosis nephrotic syndrome proteinuria repository corticotropin injection
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!